# A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™

> **NCT06320535** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oxford** · enrollment: 36 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** R21/Matrix M™ (Group 1)
- **BIOLOGICAL:** R21/Matrix M™ (Group 2)
- **BIOLOGICAL:** R21/Matrix M™ (Group 3)
- **PROCEDURE:** Fine needle aspiration (FNA)

## Key facts

- **NCT ID:** NCT06320535
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-25
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06320535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06320535, "A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06320535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*